Medical device rules eased for outsourced sterilisation; EU added to stringent regulatory jurisdictions
2-minute summary
The Union Health Ministry has amended the Medical Devices Rules, 2017, to simplify regulatory compliance and promote ease of doing business. Under the amendment to Rule 44, manufacturers outsourcing sterilization to licensed facilities no longer need a separate 'loan licence,' reducing paperwork and compliance costs while maintaining traceability by printing the facility's license number on the device label (with a six-month transition period). Additionally, the amendment to Rule 63 adds the European Union (EU) to the list of stringent regulatory jurisdictions—joining the US, UK, Australia, Canada, and Japan. This inclusion allows medical devices approved in the EU to qualify for clinical investigation waivers in India when no predicate device exists, accelerating market access for advanced medical technologies.
Why it's in the news
The Union Health Ministry has proposed and implemented key amendments to the Medical Devices Rules, 2017, aimed at easing regulatory compliance for outsourced sterilization and expanding clinical trial waiver recognitions to include the European Union.
Background and context
Medical devices in India were historically regulated under the Drugs and Cosmetics Act, 1940. To establish a dedicated, risk-based regulatory framework, the government notified the Medical Devices Rules, 2017. These rules classify medical devices into four categories (Class A, B, C, and D) based on risk. While the framework improved safety standards, industry stakeholders frequently highlighted bottlenecks, such as redundant 'loan licensing' for outsourced processes like sterilization, and lengthy clinical trial requirements for globally approved technologies. The recent amendments address these issues to align Indian regulations with global standards, supporting India's ambition to become a global hub for medical device manufacturing.
Constitutional provisions
- Article 47 — Directs the State to regard the raising of the level of nutrition and the standard of living of its people and the improvement of public health as among its primary duties.
Government schemes
- Production Linked Incentive (PLI) Scheme for Medical Devices — Aims to boost domestic manufacturing and attract large investments in the medical devices sector.
- National Medical Devices Policy, 2023 — Facilitates orderly growth of the medical device sector to meet public health objectives, access, and affordability.
International organisations
- European Union (EU) — Added to India's list of recognized stringent regulatory jurisdictions, facilitating clinical investigation waivers for EU-approved medical devices.
Mains practice: Analyze how the recent amendments to the Medical Devices Rules, 2017 balance the dual objectives of ensuring patient safety and promoting 'Ease of Doing Business' in India.
The Union Health Ministry's recent amendments to the Medical Devices Rules, 2017, represent a pragmatic regulatory shift. By simplifying compliance and aligning with global standards, the government seeks to foster industrial growth without compromising public health safety.
Promoting Ease of Doing Business:
• Reduction of Duplicative Licensing: The amendment to Rule 44 removes the requirement for a separate 'loan licence' for manufacturers outsourcing sterilization to already-licensed facilities. This reduces administrative overhead, paperwork, and compliance costs, particularly benefiting MSMEs.
• Faster Market Access: By amending Rule 63 to include the European Union (EU) alongside the US, UK, Australia, Canada, and Japan, India has expanded its list of recognized stringent regulatory jurisdictions. This allows clinical investigation waivers for advanced devices approved in the EU, drastically reducing regulatory timelines for importers and manufacturers.
Ensuring Patient Safety and Traceability:
• Robust Traceability: While the loan license requirement is eliminated, safety oversight is maintained. Manufacturers must print the sterilization facility's license number on the device label, ensuring clear accountability.
• Structured Transition: A six-month transition period allows companies to update packaging and labeling systematically, preventing supply chain disruptions while ensuring compliance.
• Reliance on High-Standard Jurisdictions: Clinical trial waivers are restricted to devices approved by globally recognized, stringent regulatory bodies, ensuring that only thoroughly tested and safe technologies enter the Indian market.
Conclusion: These amendments demonstrate that ease of doing business and patient safety are complementary. By reducing redundant red tape and embracing international regulatory convergence, India enhances its competitiveness as a medical manufacturing hub while ensuring rapid access to safe, life-saving technologies.
Prelims practice questions
Q1. With reference to the Medical Devices Rules, 2017, consider the following statements: 1. Medical devices in India are classified into four risk-based categories. 2. Under the recent amendments, the European Union (EU) has been added to the list of stringent regulatory jurisdictions recognized for clinical investigation waivers. Which of the statements given above is/are correct?
- 1 only
- 2 only
- Both 1 and 2
- Neither 1 nor 2
Answer: C. Statement 1 is correct as medical devices are classified into Class A, B, C, and D based on risk. Statement 2 is correct as the amendment to Rule 63 added the EU to the list of recognized stringent jurisdictions (joining US, UK, Australia, Canada, and Japan) to facilitate clinical trial waivers.
Q2. Under the amended Rule 44 of the Medical Devices Rules, 2017, which of the following requirements has been relaxed for medical device manufacturers?
- The requirement to pay testing fees for Class A medical devices.
- The requirement to obtain a separate loan licence for outsourced sterilization if the facility holds a valid licence.
- The requirement to print the sterilization facility's licence number on the device label.
- The requirement to conduct post-market surveillance for Class D devices.
Answer: B. The amendment to Rule 44 removes the requirement for manufacturers to obtain a separate loan licence for sterilization if they outsource the activity to a facility that already holds a valid licence under the Medical Devices Rules, 2017.
Q3. Which of the following countries/regions is NOT currently recognized under Rule 63 of the Medical Devices Rules, 2017 as a stringent regulatory jurisdiction for clinical investigation waivers in India?
- Australia
- China
- Japan
- United Kingdom
Answer: B. The recognized stringent regulatory jurisdictions under Rule 63 are the United States, the United Kingdom, Australia, Canada, Japan, and the newly added European Union (EU). China is not included in this list.
Revision flashcards
- Which ministry is responsible for notifying and amending the Medical Devices Rules, 2017? The Ministry of Health and Family Welfare (Union Health Ministry).
- What is the significance of adding the European Union (EU) to Rule 63 of the Medical Devices Rules? It allows medical devices approved in the EU to qualify for clinical investigation waivers in India if they do not have predicate devices.
- How is traceability maintained under the amended Rule 44 for outsourced sterilization? Manufacturers must mention the license number of the outsourced sterilization facility on the medical device label.
- Which countries were already recognized as stringent regulatory jurisdictions under Rule 63 before the EU was added? The United States, the United Kingdom, Australia, Canada, and Japan.
- What is the transition period granted to manufacturers to update labels under the new sterilization rules (as of August 2026)? A six-month transition period is provided.